WAT

Business profile & competitive position

Waters Corporation operates in the Healthcare sector, specifically the Medical - Diagnostics & Research industry. Its core business is the design, manufacture, sale and service of analytical technologies—most notably high-performance and ultra-performance liquid chromatography (LC), mass spectrometry (MS), thermal analysis, rheometry and calorimetry (TA) instruments. Those instruments are typically sold as integrated LC-MS systems tied to common software platforms, along with recurring revenue streams from consumables, service contracts and support plans. The installed base serves pharmaceutical, clinical, biochemical, industrial, nutritional safety, environmental, academic and government laboratories. Following the February 9, 2026 acquisition of BD’s Biosciences and Diagnostic Solutions (BDS) businesses, Waters also now offers diagnostics specimen collection, infectious-disease and cancer testing systems, flow cytometry and multiomics tools.

The customer base is concentrated by sector rather than by account: in 2025, pharmaceutical customers generated 59% of net sales, other industrial accounts 30%, and academic/government agencies 11%. No single customer accounted for more than 2% of net sales. Service revenue represented more than 35% of Waters’ 2025 sales and more than 25% of TA’s 2025 sales, pointing to an installed-base-driven, recurring-revenue component within the model.

Yet the financial returns currently paint a cautionary picture of near-term competitive economics. The reported net margin is 3.6% and return on equity is only 1.9%. Those figures are unusually low for a scientific-tools business, especially one that carries a $16.8 billion acquisition on the balance sheet. The weak margins and ROE suggest that the recent BD integration, amortization and restructuring costs are compressing reported returns, and that any durable moat from instruments, software lock-in or service relationships has not yet translated into strong profitability in the post-deal financials.

Financial posture

WAT currently trades at $429.29 with a market capitalization of $42.2 billion and a trailing P/E of 106.8. That multiple is extremely high relative to the company’s current earnings power, implying that investors are pricing in substantial future growth, margin recovery and integration synergies from the BD Biosciences and Diagnostic Solutions transaction rather than trailing results. The stock’s beta is 1.19, meaning it has historically moved slightly more than the overall market, which is consistent with both a healthcare-technology growth profile and integration execution risk.

Near-term price structure shows the stock above its 50-day exponential moving average of $410.89, with an RSI of 56.1—neither overbought nor oversold. The valuation backdrop, however, is stretched: a 106.8 P/E against a 3.6% net margin and 1.9% ROE means the equity is priced for a material expansion in profitability. The $16.8 billion BDS acquisition (including assumed debt), structured as a Reverse Morris Trust, significantly enlarged the company’s asset base and changed the capital structure; BD shareholders ended up owning approximately 39.2% of the combined company. The current financials therefore reflect a business in transition rather than a steady-state scientific-tools compounder.

Strategic priorities & outlook

According to Waters’ most recent SEC 10-K filing, the company’s near-term operational focus is centered on integrating and reorganizing the combined enterprise. Management plans to reorganize the company into four segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics and Waters Materials Sciences. It also intends to evaluate those newly organized activities to determine how operating and reporting segments will be structured for future periods.

Beyond restructuring, the 10-K emphasizes continued significant R&D investment to develop new products and enhance existing LC, MS, TA and diagnostics offerings. The company also intends to pursue additional outsourcing opportunities as they arise, while maintaining adequate internal supply chain and manufacturing capabilities. Those priorities highlight that Waters sees the next few years as an integration and product-investment cycle, not merely a cost-cutting exercise. The strategic bet appears to be that combining Waters’ analytical instrumentation with BD’s biosciences and diagnostics platforms will create a broader, more recurring-revenue life-sciences business.

Macro & geopolitical exposure

As a Healthcare / Medical - Diagnostics & Research company, Waters is exposed to several macro and geopolitical factors common to the industry. Regulatory risk is central: diagnostics and medical-device products face oversight from agencies such as the FDA and comparable foreign regulators, and approvals or labeling changes can affect product rollouts. Reimbursement and payer policy also matter, especially now that diagnostics specimen collection and infectious-disease/cancer testing are part of the portfolio. Trade policy is another consideration; analytical instruments and their specialized components move through global supply chains, so tariffs, export controls or restrictions on technology transfer can affect costs and demand. Currency fluctuations influence translated international revenue. Academic and government funding cycles—relevant to the 11% of 2025 sales tied to those customers—can shift with public budgets, while roughly 59% pharmaceutical exposure means the company is tied to biopharma R&D capital spending. Commodity and logistics costs, though generally modest relative to product value, can still affect instrument margins.

Recent developments

Recent headlines show a company focused on earnings messaging and integration momentum. On October 1, 2026, Waters Corporation scheduled its third quarter 2026 earnings conference call via PR Newswire. On September 26, 2026, MarketBeat reported that Waters “Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum,” reflecting investor interest in both artificial-intelligence-related lab demand and the BD combination. On September 23, 2026, Seeking Alpha published the transcript of Waters’ presentation at the U.S. All Stars Conference, giving management a venue to discuss strategy. A day earlier, on September 22, 2026, Zacks ran “Still Waters Bring Mixed Pre-Market Levels,” which captures the cross-currents around the stock heading into the quarter.

Collectively, the news flow points to an upcoming catalyst: the next scheduled earnings release is November 3, 2026 before the market open, with a consensus EPS estimate of $4.00. The narrative is split between optimism around AI-driven lab demand and BD integration on one hand, and digestion of a steep valuation and a major acquisition on the other.

Earnings behavior & post-earnings drift

WAT’s recent earnings track record is technically perfect but the surprises have been moderate. Over the last eight reported quarters the company beat the official consensus EPS estimate every time, for a beat rate of 8 out of 8 (100%), with an average earnings surprise of 4.7%. The average 5-day price move in the five trading days following those releases has been 2.67%, classified as an “up” drift.

The four most recent quarters illustrate the pattern, with one notable exception. On August 4, 2026, Waters reported EPS of $3.05 versus an estimate of $3.01, a 1.3% surprise; the stock rose 0.99% the next day and 4.78% over the following five days. On May 5, 2026, EPS came in at $2.70 versus $2.31 estimated, a 16.9% surprise, producing a 2.04% next-day gain and a 2.83% five-day gain. On February 9, 2026, the company earned $4.53 against a $4.51 estimate, only a 0.4% surprise; the stock dipped 0.34% the next day and fell 2.04% over the next five sessions. The November 4, 2025 report, with EPS of $3.40 versus $3.21 (5.9% surprise), drove a 1.26% next-day rally and a 5.12% five-day advance.

Because the company has beaten in every quarter, the market’s real expectation may have shifted above the published consensus; even a modest miss or smaller-than-average beat could carry outsized price risk. That said, the average post-earnings drift has been positive, suggesting that on balance the market has rewarded Waters’ announcements over the subsequent week.

For a deeper dive into institutional conviction, target revisions and forward modeling around the BD integration, look at the full institutional verdict on the ticker page.